Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR
- PMID: 35895233
- DOI: 10.1007/s10620-022-07623-4
Individualization of HCC and Portal Hypertension Surveillance in Patients with Compensated Advanced Chronic Liver Disease and SVR
Comment on
-
Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.Dig Dis Sci. 2023 Jan;68(1):323-332. doi: 10.1007/s10620-022-07621-6. Epub 2022 Jul 27. Dig Dis Sci. 2023. PMID: 35895234
References
-
- Mandorfer M, Kozbial K, Freissmuth C, Schwabl P, Stattermayer AF, Reiberger T et al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. Aliment Pharmacol Ther. 2015;42:707–718. - DOI
-
- Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stattermayer AF et al. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology. 2020;71:1023–1036. - DOI
-
- Lens S, Baiges A, Alvarado-Tapias E, E LL, Martinez J, Fortea JI, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020;73(6):1415–24.
-
- Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis. 2021;25:291–310. - DOI
-
- de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–974.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
